KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Net Cash Flow (2016 - 2025)

Emergent BioSolutions' Net Cash Flow history spans 16 years, with the latest figure at -$40.1 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 21.06% year-over-year to -$40.1 million; the TTM value through Dec 2025 reached $103.4 million, up 1795.08%, while the annual FY2025 figure was $103.4 million, 1795.08% up from the prior year.
  • Net Cash Flow reached -$40.1 million in Q4 2025 per EBS's latest filing, down from -$21.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $400.5 million in Q4 2022 to a low of -$343.6 million in Q2 2023.
  • Average Net Cash Flow over 5 years is -$20.6 million, with a median of -$36.4 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: crashed 638.24% in 2021, then skyrocketed 4594.74% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $172.3 million in 2021, then surged by 132.44% to $400.5 million in 2022, then crashed by 93.66% to $25.4 million in 2023, then plummeted by 300.0% to -$50.8 million in 2024, then rose by 21.06% to -$40.1 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Net Cash Flow are -$40.1 million (Q4 2025), -$21.6 million (Q3 2025), and $117.2 million (Q2 2025).